SuperworthPalisade Bio PALI
- Market cap
- $231.8M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $0 | $0 | $0 | $0 | $0 | $0 | n/a | $0 | n/a | n/a | n/a | $500K | |
| R&D | $2.1M+9% | $1.4M−42% | $2.2M+78% | $2.6M+21% | $2.1M+2% | $2.1M+52% | $950K−57% | $1.7M−36% | $1.4M−35% | $6.2M+196% | $6.4M+573% | $7.4M+342% |
| SG&A | $1.7M−19% | $1.6M+4% | $1.5M−5% | $1.6M+11% | $1.5M−13% | $1.3M−17% | $1.4M−7% | $1.2M−26% | $1.5M+5% | $3.8M+193% | $4.4M+220% | $4.8M+311% |
| −$3.8M−14% | −$3.2M−18% | −$3.7M+45% | −$4.2M+17% | −$3.6M−5% | −$3.4M+7% | −$2.3M−37% | −$2.8M−33% | −$2.9M−19% | −$10M+195% | −$10.7M+365% | −$11.7M+312% | |
| Interest expense | $8K+100% | $4K+33% | $1K | $2K−33% | $6K−25% | $3K−25% | $1K+0% | $2K+0% | $5K−17% | $2K−33% | $1K+0% | $0 |
| Net income | −$3.6M−10% | −$3M−20% | −$3.5M+51% | −$4.1M+20% | −$3.5M−3% | −$3.3M+13% | −$2.2M−37% | −$2.8M−32% | −$2.9M−18% | −$8.9M+166% | −$9.6M+331% | −$10.6M+280% |
| −$7.38−88% | −$4.82−86% | −$4.59−44% | −$3.32−58% | −$2.32−69% | −$1.55−68% | −$0.47−90% | −$0.58−83% | −$0.38−84% | n/a | −$0.05−89% | −$0.05−91% | |
| 489.6K+654% | 616.1K+415% | 768.1K+167% | 1.2M+187% | 1.5M+206% | 2.2M+250% | 4.8M+524% | 4.8M+291% | 7.5M+398% | n/a | 209.7M+4272% | 211.4M+4306% |
EPS, diluted: 12 periods, Q4 FY10 to Q4 FY24: quarter's net income to common over its shares, to the cent.
Diluted shares: 13 periods, Q4 FY10 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY22: a loss quarter: its basic count, share-days: the 12-month average over 365 days less the 9-month over 273, the two on one basis (x50).
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Biotechnology nearest Palisade Bio's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| PALIPalisade Bio | $231.8M | n/m | n/a | n/m | n/m | n/m | |
| PLXProtalix BioTherapeutics | $205.5M | 11.1× | 34.2× | 2.5× | +30% | 23.5% | |
| MGTXMeiraGTx | $884.6M | 13.0× | 18.0× | 2.2× | n/m | 19.9% | |
| VCELVericel | $2.2B | 92.5× | 158× | 7.1× | +23% | 7.9% | |
| Peer median | $884.6M | 13.0× | 34.2× | 2.5× | +27% | 19.9% |
More on Palisade Bio
Each number over time
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .